<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539041</url>
  </required_header>
  <id_info>
    <org_study_id>CNIO752A02101</org_study_id>
    <nct_id>NCT04539041</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy</brief_title>
  <official_title>A Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered NIO752 in Participants With Progressive Supranuclear Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation&#xD;
      study with NIO752 in progressive supranuclear palsy (PSP) participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation&#xD;
      study with NIO752 in progressive supranuclear palsy (PSP) participants.&#xD;
&#xD;
      Approximately 64 PSP participants in 6 cohorts will be randomized to receive NIO752 or&#xD;
      placebo in a ratio of 3:1. Intrathecal ( IT ) injections of NIO752 or placebo will be given 4&#xD;
      times over 3 months. All participants will remain in this study for an additional 9 month&#xD;
      follow-up period with 6 scheduled visits.&#xD;
&#xD;
      Cohorts will be enrolled sequentially.&#xD;
&#xD;
      Safety assessments will include physical and neurological examinations, ECGs, vital signs,&#xD;
      standard clinical laboratory evaluations (hematology, blood chemistry, and urinalysis), CSF&#xD;
      laboratory test, adverse event, and serious adverse event monitoring.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 16, 2021</start_date>
  <completion_date type="Anticipated">January 16, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 17, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events and serious adverse events</measure>
    <time_frame>Baseline up to approximately one year (3 month treatment plus 9 month follow-up)</time_frame>
    <description>Adverse events will be collected at clinical visits and other contacts. All abnormalities from safety assessments (physical exams and neurological exams and clinical safety labs) considered clinically significant will be recorded as adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in severity scores for Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Baseline up to approximately 1 year (3 month treatment plus 9 month follow-up)</time_frame>
    <description>The Columbia-Suicide Severity Rating Scale (C-SSRS) is a questionnaire that prospectively assesses Suicidal Ideation and Suicidal Behavior. The C-SSRS must be administered at visits. If, at any time after &quot;screening and/or baseline&quot; version, the score is &quot;yes&quot; on item 4 or item 5 of the Suicidal Ideation section of the C-SSRS or &quot;yes&quot; on any item of the Suicidal Behavior section, the participant must be referred to a mental health care professional for further assessment and/or treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of infection indicators in Cerebrospinal fluid (CSF)</measure>
    <time_frame>Baseline up to approximately 1 year (3 month treatment plus 9 month follow-up)</time_frame>
    <description>CSF safety labs measure levels of proteins, glucose, lactate and white blood cell counts with differential indicating infections.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentrations of NIO752 in blood plasma</measure>
    <time_frame>From the 1st dose administration (day 1), through study completion, where the longest duration would be approximately 1 year for those who receive 4 treatment doses</time_frame>
    <description>concentrations of NIO752 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of NIO752 in CSF</measure>
    <time_frame>From the 1st dose administration (day 1), through study completion, where the longest duration would be approximately 1 year for those who receive 4 treatment doses</time_frame>
    <description>concentrations of NIO752 in CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, Ctrough in blood plasma</measure>
    <time_frame>From the 1st dose administration (day 1), through study completion, where the longest duration would be approximately 1 year for those who receive 4 treatment doses</time_frame>
    <description>Maximum and trough level concentrations of NIO752 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax in blood plasma</measure>
    <time_frame>From the 1st dose administration (day 1), through study completion, where the longest duration would be approximately 1 year for those who receive 4 treatment doses</time_frame>
    <description>Time of Cmax in plasma post first injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast in blood plasma</measure>
    <time_frame>0 to 24 hours after first injection</time_frame>
    <description>Area under curve (AUC) from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf in blood plasma</measure>
    <time_frame>0 to 24 hours after first injection</time_frame>
    <description>The AUC from time zero to infinity (mass x time x volume-1)</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Progressive Supranuclear Palsy (PSP)</condition>
  <arm_group>
    <arm_group_label>Cohort A NIO752</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 injections of NIO752 at dose A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B NIO752</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 injections of NIO752 at dose B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 injections of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C NIO752</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 injections of NIO752 at dose C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D NIO752</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 injections of NIO752 at dose D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E NIO752</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 injections of NIO752 at dose E</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F NIO752</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 injections of NIO752 at dose F</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antisense oligonucleotide</intervention_name>
    <description>solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels</description>
    <arm_group_label>Cohort A NIO752</arm_group_label>
    <arm_group_label>Cohort B NIO752</arm_group_label>
    <arm_group_label>Cohort C NIO752</arm_group_label>
    <arm_group_label>Cohort D NIO752</arm_group_label>
    <arm_group_label>Cohort E NIO752</arm_group_label>
    <arm_group_label>Cohort F NIO752</arm_group_label>
    <other_name>NIO752</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo for each dose level</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Between 40 to 75 years old (inclusive)&#xD;
&#xD;
          3. Have PSP diagnosed for less than 5 years with a current classification of probable PSP&#xD;
             Richardson syndrome, a progressive supranuclear palsy rating scale (PSPRS) score &lt; 40&#xD;
             and MOCA score &gt;17 at screening&#xD;
&#xD;
          4. Be able to ambulate independently or able to take at least 5 steps with minimal&#xD;
             assistance&#xD;
&#xD;
          5. At least a 12-month history of postural instability or falls within 3 years from&#xD;
             disease onset as per medical history&#xD;
&#xD;
          6. Vertical supranuclear gaze palsy, or reduced velocity of vertical saccade&#xD;
&#xD;
          7. Able and willing to meet all study requirements including:&#xD;
&#xD;
             Have a study partner who is reliable, competent, and at least 18 years of age, and&#xD;
             will be able to accompany the participant to study visits, be knowledgeable of the&#xD;
             participant's ongoing condition during the study to provide study related information&#xD;
             to study site when required both in person and via a phone Reside in a proximity to&#xD;
             the study site to allow a timely unscheduled visit if necessary (ideally less than 2&#xD;
             hours) Able to undergo lumbar puncture (LP), CSF draws and blood draws&#xD;
&#xD;
          8. If the participant is receiving levodopa/carbidopa, levodopa/benserazide, a dopamine&#xD;
             agonist, catechol-o-methyltransferase (COMT) inhibitor, rasagiline, CoQ10 or other&#xD;
             Parkinson's medications, acetylcholinesterase inhibitors, antipsychotics, memantine,&#xD;
             or other non-tau modifying Alzheimer's medication the dose must have been stable for&#xD;
             at least 30 days prior to the screening visit and must remain stable for the duration&#xD;
             of the study. No such medication can be initiated during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Live in a skilled nursing facility or dementia care facility&#xD;
&#xD;
          2. Evidence of motor neuron disease, or any other neurological disease that could explain&#xD;
             symptoms&#xD;
&#xD;
          3. Clinically significant laboratory abnormality&#xD;
&#xD;
          4. Attempted suicide, suicidal ideation with a plan that required hospital admission&#xD;
             within 12 months prior to Screening. In addition, patients deemed by the Investigator&#xD;
             to be at significant risk of suicide, major depressive episode, psychosis, confusion&#xD;
             state, or violent behavior should be excluded.&#xD;
&#xD;
          5. A clear and robust benefit from levodopa by history&#xD;
&#xD;
          6. Use of lithium, methylene blue or other putative disease modifying drugs for PSP&#xD;
             within 30 days of screening&#xD;
&#xD;
          7. Any previous use of experimental therapy within 30 days or 5 half-lives prior to Day&#xD;
             1, whichever is greater&#xD;
&#xD;
          8. Any condition that increases risk of meningitis unless participant is receiving&#xD;
             appropriate prophylactic treatment&#xD;
&#xD;
          9. History of post-lumbar-puncture headache of moderate or severe intensity and/or blood&#xD;
             patch&#xD;
&#xD;
        11. Hospitalization for any major medical or surgical procedure involving general&#xD;
        anesthesia within 12 weeks of Screening or planned during the study 12. Unable to undergo&#xD;
        magnetic resonance imaging (MRI) due to for example claustrophobia, or presents absolute&#xD;
        contraindications to MRI (e.g., metallic implants, metallic foreign bodies, pacemaker,&#xD;
        defibrillator) 13. Patients with other significant brain MRI abnormalities by history or at&#xD;
        screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>progressive supranuclear palsy</keyword>
  <keyword>PSP</keyword>
  <keyword>antisense oligonucleotide</keyword>
  <keyword>ASO</keyword>
  <keyword>tau</keyword>
  <keyword>NIO752</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

